Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of BL-M07D1 versus physician's choice in HER2 IHC3+ advanced colorectal cancer after oxaliplatin, fluoropyrimidine, and irinotecan failure
CTR20262868Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1 in colorectal cancer (CRC), sponsored by Biokin Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
BL-M07D1
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20262868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262868.